Previous close | 1.7800 |
Open | 2.2600 |
Bid | 1.9500 |
Ask | 2.5500 |
Strike | 60.00 |
Expiry date | 2024-11-15 |
Day's range | 2.2600 - 2.2600 |
Contract range | N/A |
Volume | |
Open interest | 65 |
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
The Relative Strength (RS) Rating for Intra-Cellular Therapies stock entered a new percentile Thursday, with a rise from 75 to 87. This unique rating tracks technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the last 52 weeks matches up against the rest of the market.
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.